This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Multifocal motor neuropathyMultifocal Motor Neuropathy (MMN)

Contents and key points
ItemDetails
A. Classification codesICD-10: G61.8 | Special Copayment Reduction: V126 | Coverage period: 5 years
B. SynonymsMultifocal motor neuropathy (MMN), multifocal motor neuropathy with conduction block, mononeuropathy multiplex with conduction block
C. Adult onsetLikelihood of first onset in adulthood: high — Mostly occurs in adults aged 20–50, and pediatric onset is very rare
1. HistoryFirst described in 1988 by Parry, Clarke, Roth, and others as a pure motor conduction block neuropathy; association with anti-GM1 IgM antibodies and efficacy of IVIG treatment established in the 1990s
2. CausesAutoimmune mechanism; anti-GM1 IgM antibodies (~50%) target GM1 ganglioside at the nodes of Ranvier of motor nerves, causing conduction block
3. GeneticsNot a hereditary disease; autoimmune disease; mechanisms of B cell dysfunction and IgM overproduction under study; specific HLA associations reported
4. General epidemiologyIncidence about 0.6–2 per 100,000; male predominance (M:F = 2.6:1); peak incidence in the 20s–50s; diagnostic delay is common (average several years)
5. PathophysiologyAnti-GM1 IgM antibodies → binding at nodes of Ranvier of motor nerves → complement activation → sodium channel dysfunction → conduction block; sensory nerves spared
6. SymptomsAsymmetric distal limb weakness (upper-limb predominant), muscle atrophy, muscle cramps, fasciculations; no sensory abnormalities; slow progression; differentiation from ALS is important
7. SignsAsymmetric distal weakness (upper limbs first), reduced or absent tendon reflexes, muscle atrophy (chronic progression), fasciculations; sensory system normal
8. ScreeningSuspect MMN in asymmetric distal motor weakness in adult men; anti-GM1 IgM antibody screening; nerve conduction studies (confirmation of conduction block)
9. DiagnosisNerve conduction studies (conduction block at multiple non-compression sites), anti-GM1 IgM antibodies, MRI (nerve thickening), application of EFNS/PNS diagnostic criteria
10. TreatmentIVIG (2 g/kg, the only approved treatment) is the standard for maintenance therapy; steroids and plasma exchange ineffective; rituximab used in IVIG-resistant cases
11. PrognosisChronic progressive course; most stabilize or improve with IVIG; cure rare, and long-term maintenance therapy for decades needed; long-term functional decline accumulates
12. PreventionNo specific prevention; minimize functional decline with early diagnosis and long-term IVIG maintenance; diagnostic education to prevent misdiagnosis as ALS is important
References10 key references (including PMID/DOI)

1. History

Multifocal motor neuropathy (MMN) is a disease recognized relatively recently as an independent clinical entity. In 1988, Parry and Clarke first described a new type of neuropathy characterized by asymmetric motor weakness and persistent conduction block confirmed on nerve conduction studies. Around the same time, Roth, Chad, and others also reported similar case series, and pure motor involvement and conduction block emerged as the core features.

In the 1990s, as it was revealed that anti-GM1 IgM antibodies are detected in about 40–50% of MMN patients, the autoimmune mechanism drew attention. In addition, in 1993–1994 multiple research groups reported that high-dose IVIG has a dramatic therapeutic effect in MMN, and IVIG was subsequently established through randomized controlled trials as the only approved treatment. It was also confirmed that steroids and plasma exchange are ineffective in MMN or may even worsen it. Since the 2000s, the diagnostic criteria of the European Federation of Neurological Societies (EFNS) and the Peripheral Nerve Society (PNS) have been refined, systematizing differentiation from motor neuron diseases such as ALS.

2. Causes

MMN is an acquired motor neuropathy caused by an autoimmune mechanism. The exact cause of onset has not been fully elucidated, but IgM autoantibodies to the ganglioside GM1 of motor nerves are understood to play a key role. Anti-GM1 IgM antibodies are detected in about 40–50% of all MMN patients, and these antibodies are regarded as both a diagnostic marker and a major factor in the pathogenic mechanism.

When anti-GM1 IgM antibodies bind to GM1 ganglioside located at the nodes of Ranvier of motor nerves, complement activation and dysfunction of voltage-gated sodium channels are induced, causing conduction block. Interestingly, GM1 ganglioside is also expressed in sensory nerves, but the fact that sensory nerves are not involved in MMN is explained by the particularly high density of GM1 expression and microstructural differences at the nodes of Ranvier of motor nerves. In anti-GM1 IgM antibody-negative MMN patients, antibodies to other anti-ganglioside complexes (e.g., GM1-GalNAc-GD1a) or to as yet unidentified antigens may play a role. The association of MMN with specific preceding infections or environmental exposures is less clear than for GBS.

3. Genetics

MMN is not a hereditary disease and is not caused by a single-gene mutation. Familial occurrence is very rare, and literature supporting it is also limited. MMN onset is due to an autoimmune mechanism, and the possibility that genetic background may influence the regulation of immune responses is under study.

Some studies have reported associations between specific HLA (human leukocyte antigen) alleles and MMN risk or anti-GM1 IgM antibody production, but there are as yet no consistent results. B cell dysfunction and the mechanism of IgM overproduction are the main immunological features of MMN, and the role of T cells is relatively less emphasized. There is also a hypothesis that a family history of autoimmune disease may increase MMN risk, but this is not an established fact. Acquired dysregulation of the immune system is currently understood to play a more important role in onset than genetic predisposition. Therefore, genetic testing of the families of MMN patients is not indicated in clinical practice.

4. General epidemiology

MMN is a rare disease, and accurate estimation of prevalence is not easy. In a large Dutch study, the prevalence was reported as about 0.6 per 100,000 population. The incidence is estimated at about 0.1–0.2 per 100,000 population per year. Diagnostic difficulty and misdiagnosis as other motor neuron diseases such as ALS lead to underestimation of the actual prevalence.

MMN shows a far higher incidence in men, with a male-to-female ratio reported at about 2.6:1. Age of onset is mainly in adults aged 20–50, with a median age of onset of about 35–40 years. Pediatric onset is very rare, and onset in older adults aged 65 or over is also uncommon. MMN is known to take an average of several years to diagnose, because early symptoms are mild and nonspecific and differentiation from ALS is difficult. Comparative epidemiological studies worldwide are limited, so regional differences in incidence are not clearly known.

5. Pathophysiology

The core of the pathogenic mechanism of MMN is dysfunction of the nodes of Ranvier of motor nerves caused by anti-GM1 IgM antibodies. GM1 ganglioside is expressed at high density at the nodes of Ranvier of peripheral nerves, especially at the nodal regions of motor nerve axons. When anti-GM1 IgM antibodies bind at this site, the following series of pathological processes proceeds.

First, after antibody binding, the classical complement pathway is activated. The membrane attack complex (MAC, C5b-9) forms on the axonal membrane at the node of Ranvier, causing local membrane damage. Second, the distribution and function of voltage-gated sodium channels (Nav1.6, etc.) and potassium channels at the node are disrupted, blocking conduction of action potentials. This conduction block can occur even without myelin damage (nondemyelinating conduction block), so morphological myelin changes are sometimes difficult to observe. Third, chronically persistent antibody-mediated damage can eventually lead to secondary axonal damage and atrophy, resulting in irreversible loss of function that is not reversed by IVIG.

The reason sensory nerves are spared is presumed to be that the expression density and microstructural arrangement of GM1 at the nodes of Ranvier of motor nerves differ from those of sensory nerves. It is also being studied whether, in the approximately 50% of MMN patients without anti-GM1 IgM antibodies, antibodies to other ganglioside complexes or currently unknown antigen targets play a role.

6. Symptoms

The core clinical feature of MMN is pure motor nerve involvement. The main symptom is asymmetric, slowly progressive motor weakness with absent or extremely mild sensory symptoms. This clinical picture resembles ALS (amyotrophic lateral sclerosis), so differential diagnosis is very important.

Motor symptoms: Asymmetric distal limb weakness is typical, with the upper limbs affected before the lower limbs. In particular, distal muscles such as the wrist extensors, finger extensors, and hypothenar muscles weaken early. Rather than worsening rapidly over days to weeks, symptoms progress slowly over months to years. Progression is so slow that patients sometimes do not notice symptoms for a long time. Muscle atrophy confined to the distribution of the affected nerves appears and may be relatively prominent with chronic progression.

Muscle cramps and fasciculations: Cramps and fasciculations may be observed in affected muscles. This makes it difficult to distinguish from ALS, but important points of differentiation in MMN are that the distribution of weakness follows nerve distributions and that there are no upper motor neuron signs (hyperreflexia, pathological reflexes).

No sensory symptoms: Involvement of pure motor nerves only is the defining feature of MMN. Patients do not complain of pain, tingling, sensory loss, and so on. Even if mild sensory symptoms are present, it can be compatible with a diagnosis of MMN as long as there is no clinically significant decline in sensory nerve function.

Other symptoms: Cranial nerve involvement (facial nerve, hypoglossal nerve) has rarely been reported but is very exceptional. Respiratory muscle involvement is extremely rare. There are also no autonomic symptoms.

7. Signs

The main signs on physical examination provide decisive clues for diagnosing MMN and differentiating it from ALS. The absence of upper motor neuron signs (hyperreflexia, Babinski sign, spasticity) is the key point of differentiation from ALS.

Pattern of weakness: Asymmetric distal weakness following nerve distributions is typical. For example, a pattern in which only the radial nerve territory is weak while adjacent nerve territories are spared. Weakness is assessed in detail with the MRC scale and recorded against nerve distribution maps.

Reflex changes: Tendon reflexes are reduced or absent in the distribution of the affected nerves. Reflexes in unaffected territories are normal. Hyperreflexia does not occur in MMN, and if hyperreflexia is observed, it strongly suggests ALS or another upper motor neuron disease.

Muscle atrophy: Atrophy progresses in chronically affected muscles. Atrophy patterns specific to the affected territory (e.g., interosseous muscle atrophy, tibialis anterior atrophy in the lower limb) are observed.

Fasciculations: There may be fasciculations visible to the naked eye or confirmed on electromyography, which are signs of a lower motor neuron lesion.

Normal sensory system: All sensory modalities (touch, pain, temperature, proprioception, vibration) are preserved as normal. If there are clinically significant sensory abnormalities, CIDP or another sensorimotor neuropathy should be considered rather than MMN.

8. Screening

Early recognition of MMN is very important for preventing misdiagnosis as ALS and providing appropriate treatment. When the following combination of clinical features is present, MMN should be actively suspected and screening tests performed.

Criteria for clinical suspicion: Adult (especially male), asymmetric distal upper-limb weakness, no sensory symptoms, slow progression over several years, no upper motor neuron signs (absence of hyperreflexia, spasticity, and Babinski sign). This combination raises the clinical suspicion toward MMN in differentiation from ALS.

Anti-GM1 IgM antibody testing: Anti-GM1 IgM antibodies are measured in serum. A positive result (~50%) strongly supports a diagnosis of MMN. However, a negative result does not exclude MMN. An antibody panel for ganglioside complexes (GM1-GalNAc-GD1a, etc.) may also be performed additionally.

Nerve conduction studies first: Confirmation of persistent motor conduction block at non-compression sites is key. Sensory nerve conduction studies should be normal. If conduction block is confirmed, a definite or probable diagnosis of MMN is applied according to the EFNS/PNS criteria.

9. Diagnosis

Diagnosis of MMN is made by combining clinical, electrophysiological, and serological testing, applying the EFNS/PNS diagnostic criteria (revised 2010).

Nerve conduction studies (NCS): The key to diagnosing MMN. Persistent motor conduction block at non-compression sites must be confirmed. Definition of conduction block: on proximal stimulation, the CMAP (compound muscle action potential) area is reduced by 50% or more compared with distal stimulation, and the duration is normal or increased by no more than 15%. Sensory nerve conduction must be normal. Conduction velocity is generally preserved or mildly reduced. F waves: may be delayed or absent.

Anti-GM1 IgM antibodies: Measured by ELISA; a positive result (~50%) supports a diagnosis of MMN. Even if negative, diagnosis is possible if clinical and electrophysiological findings are consistent. It is important to distinguish them from anti-GM1 IgG antibodies (positive in other diseases such as ALS), and the isotype (IgM vs IgG) should be specified.

MRI: T2 hyperintensity and thickening of the brachial plexus or affected nerves (possible even without gadolinium enhancement) may be observed. This supports a diagnosis of MMN but is not essential. Spinal cord MRI confirms the absence of upper motor neuron lesions (corticospinal tract degeneration), excluding ALS.

Cerebrospinal fluid examination: Generally normal or with mildly elevated protein. There is no pleocytosis. It helps differentiate MMN from CIDP (markedly elevated protein).

Diagnostic trial of IVIG: When clinical and electrophysiological findings are consistent with MMN but confirmation is difficult, confirming clinical improvement after IVIG administration can be used as an approach that serves both diagnosis and treatment.

10. Treatment

For MMN, IVIG is currently the only officially approved treatment in the United States (FDA) and Europe. Steroids and plasma exchange are ineffective in MMN or may even cause clinical worsening, so they are regarded as quasi-contraindicated.

IVIG: For induction, 2 g/kg is administered over 2–5 days. Most patients experience improvement in strength within days to weeks after treatment. However, the effect is temporary, so repeated maintenance treatment is needed. Maintenance dose and interval should be individualized; generally 0.5–1 g/kg is given repeatedly every 4–8 weeks. Because gradual functional decline may occur even with long-term treatment, periodic clinical assessment (grip strength, functional scales) is needed.

Steroids and plasma exchange: In MMN, steroids (oral prednisolone, intravenous methylprednisolone) have been confirmed to be ineffective, and clinical worsening was observed in some reports. Plasma exchange also shows no meaningful effect in MMN. Neither treatment is recommended for MMN.

Rituximab: An anti-CD20 monoclonal antibody that depletes B cells and suppresses production of anti-GM1 IgM antibodies. It is used off-label in resistant cases with very high IVIG dependence or an insufficient response to IVIG. Small studies and case reports have observed reduced IVIG requirements or functional improvement in some patients, but large randomized controlled trials are still lacking. Regimens of 375 mg/m² weekly for 4 weeks or 1,000 mg twice (2 weeks apart) are used.

Other treatments under study: Eculizumab (complement C5 inhibitor), inebilizumab, and others are being studied in MMN, and as of 2025 there are no established additional treatments. Maintaining function through physical and occupational therapy and the use of assistive devices are important.

11. Prognosis

The natural course of MMN is chronically progressive. With IVIG treatment, clinical stabilization or temporary improvement is possible in most patients, but complete remission is rare, and long-term treatment over decades is needed.

An initial clinical response (improvement or stabilization of strength) is seen in about 80–90% of patients receiving IVIG treatment. However, the effect of IVIG diminishes over time, and slow functional decline accumulates in most patients. In long-term follow-up studies, decline in activities of daily living is observed in a considerable proportion of patients after decades.

Poor prognostic factors: diagnostic delay (misdiagnosis due to negative anti-GM1 IgM antibodies), axonal damage already present before starting treatment (irreversible muscle atrophy), and prominent lower-limb involvement. The association between anti-GM1 IgM antibody positivity and prognosis is inconsistent. Direct death is rare, and respiratory failure is also extremely exceptional. The main morbidity is occupational and daily disability due to decline in hand and upper-limb function.

12. Prevention

No specific method of preventing the development of MMN is currently known. As a disease caused by an autoimmune mechanism, no environmental modifiable factors that can reduce the risk of onset have been established either. Prevention strategies focus mainly on early diagnosis, maintaining optimal treatment, and preserving function.

Importance of early diagnosis: If diagnosis is delayed, irreversible axonal damage accumulates during that period, leading to long-term functional decline. Therefore, including MMN in the differential diagnosis of asymmetric distal motor weakness in adult men and performing nerve conduction studies and anti-GM1 IgM antibody testing early is the practical 'preventive approach'.

Preventing misdiagnosis as ALS: A considerable proportion of MMN patients are misdiagnosed with ALS and go years without treatment. This can be prevented through clinical education and systematic application of electrophysiological testing.

Optimizing IVIG maintenance therapy: When treatment efficacy diminishes (secondary failure), shortening the dosing interval or increasing the dose is considered. During long-term treatment, treatment efficacy is monitored with periodic functional assessment (grip strength measurement, upper-limb functional scales). Physical and occupational therapy are provided concurrently to maintain remaining function as much as possible.

References

  1. Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75(9):818-825. PMID: 20805527
  2. van Schaik IN, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol. 2006;13(8):802-808. PMID: 16879289
  3. Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2012;8(1):48-58. PMID: 22105212
  4. Léger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001;124(1):145-153. PMID: 11133795
  5. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology. 1994;44(3 Pt 1):429-432. PMID: 8145912
  6. Lahrmann H, Grisold W, Authier FJ, Zifko UA. Multifocal motor neuropathy with conduction block: a study of 25 patients. J Neurol. 2001;248(3):187-193. PMID: 11374079
  7. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with nodo-paranodopathy. J Neurol Neurosurg Psychiatry. 2011;82(12):1359-1361. PMID: 21836026
  8. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 2001;115(1-2):4-18. PMID: 11282147
  9. Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of multifocal motor neuropathy: a follow up study of 18 patients over a mean period of 10 years. J Neurol Neurosurg Psychiatry. 2006;77(2):209-212. PMID: 16421123
  10. Harschnitz O, van den Berg LH, Johansen LE, et al. Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. Ann Neurol. 2016;80(1):71-88. PMID: 27159063